Critical Review: Vigil Neuroscience (NASDAQ:VIGL) and DBV Technologies (NASDAQ:DBVT)

DBV Technologies (NASDAQ:DBVT) and Vigil Neuroscience (NASDAQ:VIGL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings for DBV Technologies and Vigil Neuroscience, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1	0	2	0	2.33
Vigil Neuroscience	1	0	3	0	2.50

DBV Technologies currently has a consensus price target of $5.00, suggesting a potential upside of 635.29%. Vigil Neuroscience has a consensus price target of $17.40, suggesting a potential upside of 495.89%. Given DBV Technologies’ higher probable upside, equities analysts plainly believe DBV Technologies is more favorable than Vigil Neuroscience.

Valuation & Earnings

This table compares DBV Technologies and Vigil Neuroscience’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$15.73 million	8.34	-$72.73 million	($0.39)	-1.74
Vigil Neuroscience	N/A	N/A	-$82.64 million	($2.13)	-1.37

DBV Technologies has higher revenue and earnings than Vigil Neuroscience. DBV Technologies is trading at a lower price-to-earnings ratio than Vigil Neuroscience, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 83.6% of Vigil Neuroscience shares are held by institutional investors. 0.6% of DBV Technologies shares are held by company insiders. Comparatively, 33.5% of Vigil Neuroscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk and Volatility

DBV Technologies has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, Vigil Neuroscience has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500.

Profitability

This table compares DBV Technologies and Vigil Neuroscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-461.32%	-46.33%	-35.32%
Vigil Neuroscience	N/A	-57.26%	-49.50%

Summary

Vigil Neuroscience beats DBV Technologies on 7 of the 13 factors compared between the two stocks.

About DBV Technologies

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

About Vigil Neuroscience

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.